Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Melatonin for cognitive impairment.

S L Jansen, D A Forbes, V Duncan

    The Cochrane Database of Systematic Reviews
    |January 27, 2006
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Letter: NICE referral criteria for lower gastrointestinal alarm features - not ideal but not poor either. Authors' reply.

    Alimentary pharmacology & therapeutics·2017
    Same author

    Poor predictive value of lower gastrointestinal alarm features in the diagnosis of colorectal cancer in 1981 patients in secondary care.

    Alimentary pharmacology & therapeutics·2016
    Same author

    A systematic review and meta-analysis of screen time behaviour among North American indigenous populations.

    Obesity reviews : an official journal of the International Association for the Study of Obesity·2016
    Same author

    No increase in prevalence of somatization in functional vs organic dyspepsia: a cross-sectional survey.

    Neurogastroenterology and motility·2015
    Same author

    Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating.

    Alimentary pharmacology & therapeutics·2015
    Same author

    Interactions between ethylene-bis-nitrourethane and Gibberellic acid during the germination of lettuce seed.

    Planta·2014
    Same journal

    Interventions to prevent or cease electronic cigarette use in children and adolescents.

    The Cochrane database of systematic reviews·2026
    Same journal

    Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

    The Cochrane database of systematic reviews·2026
    Same journal

    Interventions for smoking cessation in inpatient psychiatry settings.

    The Cochrane database of systematic reviews·2026
    Same journal

    Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

    The Cochrane database of systematic reviews·2026
    Same journal

    Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

    The Cochrane database of systematic reviews·2026
    Same journal

    Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

    The Cochrane database of systematic reviews·2026
    See all related articles

    Melatonin shows no significant effect on cognitive decline in dementia patients. However, some studies suggest potential benefits for behavioral and affective symptoms, though evidence remains insufficient.

    Area of Science:

    • Neurology
    • Gerontology
    • Pharmacology

    Background:

    • Studies suggest a link between diminished melatonin function and dementia symptoms.
    • Melatonin, a hormone regulating sleep-wake cycles, is being investigated for its potential role in cognitive health.

    Purpose of the Study:

    • To review the clinical efficacy and safety of melatonin for dementia and cognitive impairment (CI).
    • To assess melatonin's impact on cognitive, behavioral, and affective symptoms in dementia patients.

    Main Methods:

    • Systematic review of randomized controlled trials (RCTs) using oral melatonin for dementia.
    • Searched Cochrane Dementia and Cognitive Improvement Group's Specialized Register for relevant studies.
    • Data extraction and meta-analysis of outcomes including cognitive, behavioral, and affective measures.

    Related Experiment Videos

    Main Results:

    • Pooled estimates showed no significant improvement in cognitive function (MMSE, ADAS-cognitive).
    • One study indicated melatonin improved behavioral/affective symptoms (ADAS non-cognitive, NPI) at 2.5 mg/day (SR), but not 10 mg/day (IR).
    • Other effects on affect, behavior, and daily living activities were largely non-significant.

    Conclusions:

    • Insufficient evidence supports melatonin's effectiveness for cognitive and non-cognitive symptoms of dementia.
    • Further research is needed to clarify melatonin's role in managing dementia manifestations.